Inhibition of breast cancer cell migration by activation of cAMP signaling

Breast Cancer Research and Treatment

Volumn 152, Issue 1, 2015, Pages 17-28

  Dong, Hongli ^a   Claffey, Kevin P ^a   Brocke, Stefan ^a   Epstein, Paul M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Breast cancer; cAMP signaling; Cell migration; Cyclic nucleotide phosphodiesterase

Indexed keywords

CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 10A; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 11A; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2A; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 3B; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4A; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4B; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4C; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4D; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 5A; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 6B; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 6C; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 7B; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 8A; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 9A; DIPYRIDAMOLE; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; PF 04957325; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE VII INHIBITOR; PHOSPHODIESTERASE VIII INHIBITOR; ROLIPRAM; SPIROQUINAZOLINONE; UNCLASSIFIED DRUG; CAMP PHOSPHODIESTERASE KINASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MIGRATION INHIBITION; PDE GENE; PDE10A GENE; PDE11A GENE; PDE2A GENE; PDE3B GENE; PDE4A GENE; PDE4B GENE; PDE4D GENE; PDE5A GENE; PDE6B GENE; PDE7A GENE; PDE7B GENE; PDE8A GENE; PDE9A GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC AMP; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84931003851     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3445-9     Document Type: Article

References (61)

1. Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12:895–904. doi:10.1038/nm1469
2. Fleming YM, Frame MC, Houslay MD (2004) PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration. J Cell Sci 117:2377–2388. doi:10.1242/jcs.01096
3. Lyle KS, Raaijmakers JH, Bruinsma W, Bos JL, de Rooij J (2008) cAMP-induced Epac-Rap activation inhibits epithelial cell migration by modulating focal adhesion and leading edge dynamics. Cell Signal 20:1104–1116. doi:10.1016/j.cellsig.2008.01.018
4. Netherton SJ, Maurice DH (2005) Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 67:263–272. doi:10.1124/mol.104.004853
5. Dua P, Gude RP (2008) Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. Eur J Cancer 44:1587–1595. doi:10.1016/j.ejca.2008.04.009
6. Murata K, Sudo T, Kameyama M, Fukuoka H, Muka M, Doki Y, Sasaki Y, Ishikawa O, Kimura Y, Imaoka S (2000) Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility. Clin Exp Metastasis 18:599–604. doi:10.1023/A:1011926116777
7. Burdyga A, Conant A, Haynes L, Zhang J, Jalink K, Sutton R, Neoptolemos J, Costello E, Tepikin A (2013) cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: effects of PKA and EPAC. Biochim Biophys Acta 1833:2664–2672. doi:10.1016/j.bbamcr.2013.06.011
8. Zimmerman NP, Roy I, Hauser AD, Wilson JM, Williams CL, Dwinell MB (2013) Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. Mol Carcinog 54:203–215. doi:10.1002/mc.22091
9. Ou Y, Zheng X, Gao Y, Shu M, Leng T, Li Y, Yin W, Zhu W, Huang Y, Zhou Y, Tang J, Qiu P, Yan G, Hu J, Ruan H, Hu H (2014) Activation of cyclic AMP/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics. Urol Oncol 32:47. e21–47. e48. doi:10.1016/j.urolonc.2013.06.017
10. Lee JW, Lee J, Moon EY (2014) HeLa human cervical cancer cell migration is inhibited by treatment with dibutyryl-cAMP. Anticancer Res 34:3447–3455
11. Baillie GS (2009) Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J 276:1790–1799. doi:10.1111/j.1742-4658.2009.06926.x
12. Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35:91–100. doi:10.1016/j.tibs.2009.09.007
13. Lomas O, Zaccolo M (2014) Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotides. Physiology 29:141–149. doi:10.1152/physiol.00040.2013
14. Conti M, Mika D, Richter W (2014) Cyclic AMP compartments and signaling specificity: role of cyclic nucleotide phosphodiesterases. J Gen Physiol 143:29–38. doi:10.1085/jgp.201311083
15. Lerner A, Epstein PM (2006) Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 393:21–41. doi:10.1042/BJ20051368
16. Francis SH, Blount MA, Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91:651–690. doi:10.1152/physrev.00030.2010
17. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13:290–314. doi:10.1038/nrd4228
18. Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V (2015) Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis 21:e25–e50. doi:10.1111/odi.12275
19. Drees M, Zimmermann R, Eisenbrand G (1993) 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 53:3058–3061
20. McEwan DG, Brunton VG, Baillie GS, Leslie NR, Houslay MD, Frame MC (2007) Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res 67:5248–5257. doi:10.1158/0008-5472.CAN-07-0097
21. O’Connor KL, Shaw LM, Mercurio AM (1998) Release of cAMP gating by the alpha6beta4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells. J Cell Biol 143:1749–1760. doi:10.1083/jcb.143.6.1749
22. Clarysse L, Gueguinou M, Potier-Cartereau M, Vandecasteele G, Bougnoux P, Chevalier S, Chantome A, Vandier C (2014) cAMP-PKA inhibition of SK3 channel reduced both Ca(2+) entry and cancer cell migration by regulation of SK3-Orai1 complex. Pflugers Arch 466:1921–1932. doi:10.1007/s00424-013-1435-5
23. Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279:509–514. doi:10.1126/science.279.5350.509
24. Raftopoulou M, Hall A (2004) Cell migration: rho GTPases lead the way. Dev Biol 265:23–32. doi:10.1016/j.ydbio.2003.06.003
25. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J (1996) Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J 15:510–519
26. O’Connor KL, Nguyen BK, Mercurio AM (2000) RhoA function in lamellae formation and migration is regulated by the alpha6beta4 integrin and cAMP metabolism. J Cell Biol 148:253–258. doi:10.1083/jcb.148.2.253
27. Serrels B, Sandilands E, Serrels A, Baillie G, Houslay MD, Brunton VG, Canel M, Machesky LM, Anderson KI, Frame MC (2010) A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Curr Biol 20:1086–1092. doi:10.1016/j.cub.2010.04.042
28. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, Muller WJ (2007) Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 104:20302–20307. doi:10.1073/pnas.0710091104
29. Dong H, Osmanova V, Epstein PM, Brocke S (2006) Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. Biochem Biophys Res Commun 345:713–719. doi:10.1016/j.bbrc.2006.04.143
30. Vang AG, Ben-Sasson SZ, Dong H, Kream B, DeNinno MP, Claffey MM, Housley W, Clark RB, Epstein PM, Brocke S (2010) PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. PLoS One 5:e12011. doi:10.1371/journal.pone.0012011
31. Brown KM, Day JP, Huston E, Zimmermann B, Hampel K, Christian F, Romano D, Terhzaz S, Lee LC, Willis MJ, Morton DB, Beavo JA, Shimizu-Albergine M, Davies SA, Kolch W, Houslay MD, Baillie GS (2013) Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc Natl Acad Sci USA 110:E1533–E1542. doi:10.1073/pnas.1303004110
32. Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69:5292–5293. doi:10.1158/0008-5472.CAN-09-1528
33. Mellor P, Deibert L, Calvert B, Bonham K, Carlsen SA, Anderson DH (2013) CREB3L1 is a metastasis suppressor that represses expression of genes regulating metastasis, invasion, and angiogenesis. Mol Cell Biol 33:4985–4995. doi:10.1128/MCB.00959-13
34. Dong H, Zitt C, Auriga C, Hatzelmann A, Epstein PM (2010) Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells. Biochem Pharmacol 79:321–329. doi:10.1016/j.bcp.2009.09.001
35. Dong H, Claffey KP, Brocke S, Epstein PM (2013) Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells. SpringerPlus 2:680. doi:10.1186/2193-1801-2-680
36. Vang AG, Housley W, Dong H, Basole C, Ben-Sasson SZ, Kream BE, Epstein PM, Clark RB, Brocke S (2013) Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac. Biochem J 456:463–473. doi:10.1042/BJ20130064
37. Terry R, Cheung YF, Praestegaard M, Baillie GS, Huston E, Gall I, Adams DR, Houslay MD (2003) Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cell Signal 15:955–971. doi:10.1016/S0898-6568(03)00092-5
38. Christian F, Anthony DF, Vadrevu S, Riddell T, Day JP, McLeod R, Adams DR, Baillie GS, Houslay MD (2010) p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. Cell Signal 22:1576–1596. doi:10.1016/j.cellsig.2010.06.003
39. Day JP, Lindsay B, Riddell T, Jiang Z, Allcock RW, Abraham A, Sookup S, Christian F, Bogum J, Martin EK, Rae RL, Anthony D, Rosair GM, Houslay DM, Huston E, Baillie GS, Klussmann E, Houslay MD, Adams DR (2011) Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4). J Med Chem 54:3331–3347. doi:10.1021/jm200070e
40. Christian F, Krause E, Houslay MD, Baillie GS (2014) PKA phosphorylation of p62/SQSTM1 regulates PB1 domain interaction partner binding. Biochim Biophys Acta 1843:2765–2774. doi:10.1016/j.bbamcr.2014.07.021
41. American Cancer Society (2015) Breast cancer key statistics. American Cancer Society, Atlanta. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics. Accessed 20 May 2015
42. Howe AK (2004) Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta 1692:159–174. doi:10.1016/j.bbamcr.2004.03.005
43. Howe AK (2011) Cross-talk between calcium and protein kinase A in the regulation of cell migration. Curr Opin Cell Biol 23:554–561. doi:10.1016/j.ceb.2011.05.006
44. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520. doi:10.1124/pr.58.3.5
45. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366–398. doi:10.1016/j.pharmthera.2005.07.003
46. Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI (2013) Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing. Transl Oncol 6:546–553. doi:10.1593/tlo.13457
47. Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA (2011) Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res 4:1275–1284. doi:10.1158/1940-6207.CAPR-11-0095
48. Saravani R, Karami-Tehrani F, Hashemi M, Aghaei M, Edalat R (2012) Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif 45:199–206. doi:10.1111/j.1365-2184.2012.00819.x
49. Kung W, Roos W, Eppenberger U (1983) Growth stimulation of human breast cancer MCF-7 cells by dibutyryl cyclic AMP. Cell Biol Int Rep 7:345–351. doi:10.1016/0309-1651(83)90074-7
50. Fentiman IS, Duhig T, Griffiths AB, Taylor-Papadimitriou J (1984) Cyclic AMP inhibits the growth of human breast cancer cells in defined medium. Mol Biol Med 2:81–88. doi:10.1016/0022-4731(83)91694-1
51. Zivadinovic D, Gametchu B, Watson CS (2005) Membrane estrogen receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation responses. Breast Cancer Res 7:R101–R112. doi:10.1186/bcr958
52. Spina A, Di Maiolo F, Esposito A, Sapio L, Chiosi E, Sorvillo L, Naviglio S (2012) cAMP elevation down-regulates beta3 integrin and focal adhesion kinase and inhibits leptin-induced migration of MDA-MB-231 breast cancer cells. BioRes Open Access 1:324–332. doi:10.1089/biores.2012.0270
53. Luker KE, Luker GD (2006) Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 238:30–41. doi:10.1016/j.canlet.2005.06.021
54. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64:8604–8612. doi:10.1158/0008-5472.CAN-04-1844
55. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK (2004) Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23:157–167. doi:10.1038/sj.onc.1206910
56. Lee BC, Lee TH, Avraham S, Avraham HK (2004) Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2:327–338
57. Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D, Rubin JB (2007) Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 67:651–658. doi:10.1158/0008-5472.CAN-06-2762
58. Yang H, Rouse J, Lukes L, Lancaster M, Veenstra T, Zhou M, Shi Y, Park YG, Hunter K (2004) Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin Exp Metastasis 21:719–735. doi:10.1007/s10585-004-8251-4
59. Spano D, Marshall JC, Marino N, De Martino D, Romano A, Scoppettuolo MN, Bello AM, Di Dato V, Navas L, De Vita G, Medaglia C, Steeg PS, Zollo M (2013) Dipyridamole prevents triple-negative breast-cancer progression. Clin Exp Metastasis 30:47–68. doi:10.1007/s10585-012-9506-0
60. Wang C, Schwab LP, Fan M, Seagroves TN, Buolamwini JK (2013) Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer. Cancer Prev Res 6:437–447. doi:10.1158/1940-6207.CAPR-12-0345
61. Choudhary S, Sood S, Wang HC (2014) Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog 53:243–252. doi:10.1002/mc.21970